Bionomics Ltd
ASX:BNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Qinhuangdao Tianqin Equipment Manufacturing Co Ltd
SZSE:300922
|
CN |
|
P
|
Parsan Makina Parcalari Sanayii AS
IST:PARSN.E
|
TR |
|
Sunstone Development Co Ltd
SSE:603612
|
CN |
Bionomics Ltd
Total Equity
Bionomics Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bionomics Ltd
ASX:BNO
|
Total Equity
AU$47.7m
|
CAGR 3-Years
62%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Bionomics Ltd
Glance View
Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The firm's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.
See Also
What is Bionomics Ltd's Total Equity?
Total Equity
47.7m
AUD
Based on the financial report for Dec 31, 2022, Bionomics Ltd's Total Equity amounts to 47.7m AUD.
What is Bionomics Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
5%
Over the last year, the Total Equity growth was -21%. The average annual Total Equity growth rates for Bionomics Ltd have been 62% over the past three years , 9% over the past five years , and 5% over the past ten years .
